|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhong Y, Lin H, Li Q, Liu C and Shen J:
CircRNA_100565 contributes to cisplatin resistance of NSCLC cells
by regulating proliferation, apoptosis and autophagy via
miR-337-3p/ADAM28 axis. Cancer Biomark. 30:261–273. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhang B and Zhang Y, Li R, Li J, Lu X and
Zhang Y: Oncolytic adenovirus Ad11 enhances the chemotherapy effect
of cisplatin on osteosarcoma cells by inhibiting autophagy. Am J
Transl Res. 12:105–117. 2020.PubMed/NCBI
|
|
4
|
Challinor JM, Alqudimat MR, Teixeira TOA
and Oldenmenger WH: Oncology nursing workforce: Challenges,
solutions, and future strategies. Lancet Oncol. 21:e564–e574.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Passarello K, Kurian S and Villanueva V:
Endometrial cancer: An overview of pathophysiology, management, and
care. Semin Oncol Nurs. 35:157–165. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tan Y, Liu D, Gong J, Liu J and Huo J: The
role of F-box only protein 31 in cancer. Oncol Lett. 15:4047–4052.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhu Z, Zheng Y, He H, Yang L, Yang J, Li
M, Dai W and Huang H: FBXO31 sensitizes cancer stem cells-like
cells to cisplatin by promoting ferroptosis and facilitating
proteasomal degradation of GPX4 in cholangiocarcinoma. Liver Int.
42:2871–2888. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Feng Y, Liu M, Xie P, Dong R and Hao Z:
FBXO31 suppresses lipogenesis and tumor progression in glioma by
promoting ubiquitination and degradation of CD147. Prostaglandins
Other Lipid Mediat. 163(106667)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Islam S, Dutta P, Sahay O, Gopalakrishnan
K, Muhury SR, Parameshwar P, Shetty P and Santra MK:
Feedback-regulated transcriptional repression of FBXO31 by c-Myc
triggers ovarian cancer tumorigenesis. Int J Cancer. 150:1512–1524.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yang HW, Xia T, Chen ZL, Feng SQ, Peng Y,
Zhou L, Gan L and Yang ZQ: Cloning, chromosomal localization and
expression patterns of porcine Kruppel-like factors 4, -5, -7 and
the early growth response factor 2. Biotechnol Lett. 29:157–163.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pei J and Grishin NV: A new family of
predicted Kruppel-like factor genes and pseudogenes in placental
mammals. PLoS One. 8(e81109)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Viola L, Londero AP, Bertozzi S, Orsaria
M, Marzinotto S, Antoniazzi F, Renda V, Cinel J, Fruscalzo A, Lellé
RJ and Mariuzzi L: Prognostic role of kruppel-like factors 5, 9,
and 11 in endometrial endometrioid cancer. Pathol Oncol Res.
26:2265–2272. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Korani M, Fallah S, Tehranian A,
Nourbakhsh M, Samadikuchaksaraei A, Pour MS and Maleki J: The
evaluation of the FOXO1, KLF9 and YT521 genes expression in human
endometrial cancer. Clin Lab. 59:483–489. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yan X, Zhang H, Ke J, Zhang Y, Dai C, Zhu
M, Jiang F, Zhu H, Zhang L, Zuo X, et al: Progesterone receptor
inhibits the proliferation and invasion of endometrial cancer cells
by up regulating Kruppel-like factor 9. Transl Cancer Res.
9:2220–2230. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fornes O, Castro-Mondragon JA, Khan A, van
der Lee R, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M,
Baranasic D, et al: JASPAR 2020: Update of the open-access database
of transcription factor binding profiles. Nucleic Acids Res.
48:D87–D92. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7(88)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang X, Zhang T, Zhang S and Shan J:
Prognostic values of F-box members in breast cancer: An online
database analysis and literature review. Biosci Rep.
39(BSR20180949)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu Y, Pan B, Qu W, Cao Y, Li J and Zhao
H: Systematic analysis of the expression and prognosis relevance of
FBXO family reveals the significance of FBXO1 in human breast
cancer. Cancer Cell Int. 21(130)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Duan S, Moro L, Qu R, Simoneschi D, Cho H,
Jiang S, Zhao H, Chang Q, de Stanchina E, Arbini AA and Pagano M:
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and
PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Rep.
37(109870)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ding N, Zhang T, Yu X and Zhuang S: T-Box
transcription factor 2 enhances chemoresistance of endometrial
cancer by mediating NRF2 expression. Curr Protein Pept Sci.
23:563–570. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lin TC, Wang KH, Chuang KH, Kao AP and Kuo
TC: Oct-4 induces cisplatin resistance and tumor stem cell-like
properties in endometrial carcinoma cells. Taiwan J Obstet Gynecol.
62:16–21. 2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lv L, Wang SC, Mo JY, Huang KL, Xu ML and
Liu J: Effects and mechanisms of FBXO31 on Taxol chemoresistance in
esophageal squamous cell carcinoma. Biochem Biophys Res Commun.
586:129–136. 2022.PubMed/NCBI View Article : Google Scholar
|
